
Atom Bioworks is a biotechnology company focused on accelerating drug discovery and development through advanced AI. Their core offering is the AptaBLE platform, a generative AI tool designed to rapidly discover and optimize aptamers, which are synthetic nucleic acid molecules that can bind to specific protein targets with high affinity and specificity. AptaBLE aims to overcome the limitations of traditional aptamer discovery methods (SELEX), offering faster development cycles, improved nuclease resistance, and reduced off-target effects compared to existing AI tools like AlphaFold for this specific application. The company also utilizes aptamer technology for cell type-specific drug delivery, particularly with AptLNP for genetic medicine, aiming to target extrahepatic tissues. Atom Bioworks has been recognized for its work, presenting at NeurIPS 2024 and joining programs like Google Cloud for Startups and NVIDIA Inception.

Atom Bioworks is a biotechnology company focused on accelerating drug discovery and development through advanced AI. Their core offering is the AptaBLE platform, a generative AI tool designed to rapidly discover and optimize aptamers, which are synthetic nucleic acid molecules that can bind to specific protein targets with high affinity and specificity. AptaBLE aims to overcome the limitations of traditional aptamer discovery methods (SELEX), offering faster development cycles, improved nuclease resistance, and reduced off-target effects compared to existing AI tools like AlphaFold for this specific application. The company also utilizes aptamer technology for cell type-specific drug delivery, particularly with AptLNP for genetic medicine, aiming to target extrahepatic tissues. Atom Bioworks has been recognized for its work, presenting at NeurIPS 2024 and joining programs like Google Cloud for Startups and NVIDIA Inception.
Headquarters: Cary / Research Triangle Park, North Carolina
Core platforms: AptaBLE (AI aptamer design), DNA STAR / DNA Net, AptLNP (targeted delivery)
Founded: 2020
Notable investors/backers: National Science Foundation, National Institutes of Health, BioTools Innovator, Y Combinator
Drug discovery, diagnostics, and targeted delivery using aptamers and DNA nanomaterials
2020
Biotechnology
Most recently listed funding event reported as a grant round
“Company lists selected investors and has received grant and early-stage support from public agencies and venture/backer organizations”